Sinopharm board to convene for Q3 results approval

Sinopharm Group Co. Ltd. announced its board of directors will hold a meeting on Friday, October 24, 2025. The primary purpose of this meeting is to consider and approve the unaudited quarterly results of the company and its subsidiaries for the nine months ended September 30, 2025. This notice was issued from Shanghai, PRC, on October 10, 2025, by order of the board, with Zhao Bingxiang serving as chairman.

The announcement also includes a disclaimer stating that Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of the notice, disclaiming any liability for losses arising from reliance on its accuracy or completeness. Sinopharm Group Co. Ltd. is a joint stock limited company incorporated in the People's Republic of China with limited liability, carrying on business in Hong Kong. The company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance.

The current executive directors of Sinopharm Group include Lian Wanyong and Sun Jinglin. The non-executive directors are Zhao Bingxiang, Chen Qiyu, Zu Jing, Xing Yonggang, Chen Yuqing, Wen Deyong, and Feng Rongli. Independent non-executive directors comprise Li Peiyu, Wu Tak Lung, Yu Weifeng, Shi Shenghao, and Chen Weiru.